Cargando…

Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy

HE4 is a commonly used tumor marker for ovarian cancer (OC) diagnosis. In our study, we aimed to assess its use in the diagnosis of subsequent OC recurrences and to evaluate its changes during recurrence diagnosis and the subsequent lines of chemotherapy treatment. This retrospective single center s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chudecka-Głaz, Anita, Strojna, Aleksandra, Michalczyk, Kaja, Wieder-Huszla, Sylwia, Safranow, Krzysztof, Skwirczyńska, Edyta, Jurczak, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913987/
https://www.ncbi.nlm.nih.gov/pubmed/36766556
http://dx.doi.org/10.3390/diagnostics13030452
_version_ 1784885558634348544
author Chudecka-Głaz, Anita
Strojna, Aleksandra
Michalczyk, Kaja
Wieder-Huszla, Sylwia
Safranow, Krzysztof
Skwirczyńska, Edyta
Jurczak, Anna
author_facet Chudecka-Głaz, Anita
Strojna, Aleksandra
Michalczyk, Kaja
Wieder-Huszla, Sylwia
Safranow, Krzysztof
Skwirczyńska, Edyta
Jurczak, Anna
author_sort Chudecka-Głaz, Anita
collection PubMed
description HE4 is a commonly used tumor marker for ovarian cancer (OC) diagnosis. In our study, we aimed to assess its use in the diagnosis of subsequent OC recurrences and to evaluate its changes during recurrence diagnosis and the subsequent lines of chemotherapy treatment. This retrospective single center study was conducted on 188 patients treated for ovarian cancer recurrence at the Department of Gynecological Surgery and Gynecological Oncology. The sensitivity and specificity of HE4 for patient survival prediction were analyzed using Receiver Operating Characteristics (ROC) and area under the curve (AUC) with 95% confidence intervals (95% CI). Survival times to reach one of the endpoints (OS, PFS, TFI, PFS2, TFI2) were analyzed using Kaplan–Meier curves. Elevated HE4 levels at the time of first relapse diagnosis, and after the third and the last course of second-line chemotherapy, significantly influences the time from OC diagnosis until first disease recurrence (PFS2) (p = 0.005, p = 0.015 and p = 0.002, respectively). Additionally, elevated serum HE4 concentration at the time of OC diagnosis (p = 0.012), and its later recurrence (first (p < 0.001), and second recurrent diagnosis (p = 0.143)) significantly influences patient OS. Increased HE4 concentration at the end of chemotherapeutic treatment negatively affects overall patient survival ((p = 0.006 for second line chemotherapy and (p = 0.022) for elevated HE4 concentration after the last course of third-line chemotherapy). Our preliminary results show an encouraging diagnostic and prognostic role of HE4 in recurrent ovarian cancer. HE4 measurements at different treatment time points during the second- and third-line chemotherapy treatment seem to correlate with patient survival.
format Online
Article
Text
id pubmed-9913987
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99139872023-02-11 Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy Chudecka-Głaz, Anita Strojna, Aleksandra Michalczyk, Kaja Wieder-Huszla, Sylwia Safranow, Krzysztof Skwirczyńska, Edyta Jurczak, Anna Diagnostics (Basel) Article HE4 is a commonly used tumor marker for ovarian cancer (OC) diagnosis. In our study, we aimed to assess its use in the diagnosis of subsequent OC recurrences and to evaluate its changes during recurrence diagnosis and the subsequent lines of chemotherapy treatment. This retrospective single center study was conducted on 188 patients treated for ovarian cancer recurrence at the Department of Gynecological Surgery and Gynecological Oncology. The sensitivity and specificity of HE4 for patient survival prediction were analyzed using Receiver Operating Characteristics (ROC) and area under the curve (AUC) with 95% confidence intervals (95% CI). Survival times to reach one of the endpoints (OS, PFS, TFI, PFS2, TFI2) were analyzed using Kaplan–Meier curves. Elevated HE4 levels at the time of first relapse diagnosis, and after the third and the last course of second-line chemotherapy, significantly influences the time from OC diagnosis until first disease recurrence (PFS2) (p = 0.005, p = 0.015 and p = 0.002, respectively). Additionally, elevated serum HE4 concentration at the time of OC diagnosis (p = 0.012), and its later recurrence (first (p < 0.001), and second recurrent diagnosis (p = 0.143)) significantly influences patient OS. Increased HE4 concentration at the end of chemotherapeutic treatment negatively affects overall patient survival ((p = 0.006 for second line chemotherapy and (p = 0.022) for elevated HE4 concentration after the last course of third-line chemotherapy). Our preliminary results show an encouraging diagnostic and prognostic role of HE4 in recurrent ovarian cancer. HE4 measurements at different treatment time points during the second- and third-line chemotherapy treatment seem to correlate with patient survival. MDPI 2023-01-26 /pmc/articles/PMC9913987/ /pubmed/36766556 http://dx.doi.org/10.3390/diagnostics13030452 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chudecka-Głaz, Anita
Strojna, Aleksandra
Michalczyk, Kaja
Wieder-Huszla, Sylwia
Safranow, Krzysztof
Skwirczyńska, Edyta
Jurczak, Anna
Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy
title Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy
title_full Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy
title_fullStr Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy
title_full_unstemmed Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy
title_short Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy
title_sort evaluation of he4 use in the diagnosis of ovarian cancer: first and second recurrence, and an analysis of he4 concentration during second- and third-line chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913987/
https://www.ncbi.nlm.nih.gov/pubmed/36766556
http://dx.doi.org/10.3390/diagnostics13030452
work_keys_str_mv AT chudeckagłazanita evaluationofhe4useinthediagnosisofovariancancerfirstandsecondrecurrenceandananalysisofhe4concentrationduringsecondandthirdlinechemotherapy
AT strojnaaleksandra evaluationofhe4useinthediagnosisofovariancancerfirstandsecondrecurrenceandananalysisofhe4concentrationduringsecondandthirdlinechemotherapy
AT michalczykkaja evaluationofhe4useinthediagnosisofovariancancerfirstandsecondrecurrenceandananalysisofhe4concentrationduringsecondandthirdlinechemotherapy
AT wiederhuszlasylwia evaluationofhe4useinthediagnosisofovariancancerfirstandsecondrecurrenceandananalysisofhe4concentrationduringsecondandthirdlinechemotherapy
AT safranowkrzysztof evaluationofhe4useinthediagnosisofovariancancerfirstandsecondrecurrenceandananalysisofhe4concentrationduringsecondandthirdlinechemotherapy
AT skwirczynskaedyta evaluationofhe4useinthediagnosisofovariancancerfirstandsecondrecurrenceandananalysisofhe4concentrationduringsecondandthirdlinechemotherapy
AT jurczakanna evaluationofhe4useinthediagnosisofovariancancerfirstandsecondrecurrenceandananalysisofhe4concentrationduringsecondandthirdlinechemotherapy